EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases

Rakin Ahmed, Khairul Anam, Hafiz Ahmed

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24098116 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Rakin Ahmed und 2 weiteren Autor:innen. Beteiligte Einrichtung: GlycoMantra Inc., Biotechnology Center, University of Maryland Baltimore County, Baltimore, MD 21250, USA. Hauptthemen laut MEDLINE: Galectin 3, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Galectin-3 (Gal3) is one of the most studied members of the galectin family that mediate various biological processes such as growth regulation, immune function, cancer metastasis, and apoptosis. Since Gal3 is pro-inflammatory, it is involved in many diseases that are associated with chronic inflammation such as cancer, organ fibrosis, and type 2 diabetes. As a multifunctional protein involved in multiple pathways of many diseases, Gal3 has generated significant interest in pharmaceutical industries. As a result, several Gal3-targeting therapeutic drugs are being developed to address unmet medical needs. Based on the PubMed search of Gal3 to date (1987–2023), here, we briefly describe its structure, carbohydrate-binding properties, endogenous ligands, and roles in various diseases. We also discuss its potential antagonists that are currently being investigated clinically or pre-clinically by the public and private companies. The updated knowledge on Gal3 function in various diseases could initiate new clinical or pre-clinical investigations to test therapeutic strategies, and some of these strategies could be successful and recognized as novel therapeutics for unmet medical needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Galectin 3Diabetes Mellitus, Type 2HumansGalectinsInflammationApoptosis

Stichwörter der Autor:innen

NASHcancerdiabetesfibrosisgalectin-3inhibitor

Substanzen

Galectin 3Galectins

Autor:innen und Institutionen

  • GlycoMantra Inc., Biotechnology Center, University of Maryland Baltimore County, Baltimore, MD 21250, USA.

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • US Army Medical Research and Materiel Command
  • Maryland Innovative Initiative grant (TEDCO)
  • National Institute of Health

Zitieren

APA

Ahmed, R., Anam, K., & Ahmed, H. (2023). Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098116

Vancouver

Ahmed R, Anam K, Ahmed H. Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098116

BibTeX
@article{Ahmed2023,
  author = {Ahmed, Rakin and Anam, Khairul and Ahmed, Hafiz},
  title = {Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24098116}
}
Kostenlos starten →